-
Long-Term Implications of HSCT-Induced Fibrosis
Maladaptive Repair The ultimate goal of regenerative medicine is the restoration of native parenchymal function. However, a critical risk exists in the administration of poorly characterized multipotent cells: the induction of maladaptive repair, wherein inflamed, functional tissue is permanently converted into non-functional fibrotic scar tissue. Aberrant Differentiation and the FOP Paradigm An extreme biological precedent…
-
Mesenchymal Immune modulation vs. Immune suppression
A Paradigm Shift in Targeted Bio-Calibration Abstract / Summary Traditional pharmacological immunosuppression relies on the systemic inactivation or depletion of immune cascades to halt tissue damage. While effective, this approach imposes a global compromise on host immunity, disrupts physiological remodeling, and risks severe off-target toxicity. In contrast, mesenchymal stromal cell (MSC)-mediated immunomodulation operates as an…
-
Autoimmune Endothelial Damage in the Post-COVID Brain
The neurological legacy of COVID-19 is increasingly understood not as a single event, but as a cascading failure of the body’s internal defenses. At the center of this crisis is hypercytokinemia—the “cytokine storm”—which can trigger a persistent autoimmune response. While much of the early clinical focus remained on pulmonary health, a more insidious form of damage…
-
The CAR-T Misconception
Deep Reset or High-Stakes Marketing? CAR-T cell-based protocols are designed to target specific cancer glycoproteins. In MS, their scope is similar to that of existing B-cell therapies, to suppress the active B-cell population in patients. CAR-T therapies come with a significantly higher price tag than existing B-cell-depleting treatments, yet they offer outcomes only comparable to…
-
Black Holes in Multiple Sclerosis
An Analytical Review of T1 Hypointensities and Imaging Methodologies For individuals navigating a diagnosis of Multiple Sclerosis (MS), reviewing an MRI report can be a deeply unsettling experience. Among the complex clinical nomenclature, few phrases provoke as much immediate, visceral anxiety as the term “black hole.” To a layperson, this phrase conjures images of an ominous, expanding…
-
US Stem Cell Legality
Exposing the Regulatory Crackdowns, Predatory Traps, and Transborder Biohazards in Modern Regenerative Medicine By Surjo Banerjee, Senior Neurobiologist | 20 Years of Contract Research Experience | Regenerative Medicine & Federal Law https://doi.org/10.13140/RG.2.2.11524.28805 In the rapidly expanding frontier of regenerative medicine, marketing narratives have vastly outpaced clinical verification. The generic umbrella term “stem cell” is routinely…
-
How CNS Medications Complicate MS
In the clinical management of Multiple Sclerosis, physicians and patients frequently encounter a profound therapeutic paradox: the trade-off between immediate symptom suppression and long-term functional recovery. To manage the anxiety, sleep disturbances, and painful spasticity associated with MS, medicine relies heavily on neuromodulating and neurosuppressive therapies. However, clamping down on central nervous system (CNS) neurotransmission to quiet overactive…
-
Limitations of aHSCT and B-Cell Depletion
The global Multiple Sclerosis (MS) therapeutics market has evolved into a staggering $31 billion annual industry. This market is heavily dominated by high-efficacy, continuous Disease-Modifying Therapies (DMTs)—specifically, anti-CD20 monoclonal antibodies (mAbs) such as ocrelizumab (Ocrevus) and ofatumumab (Kesimpta). While these biologics are exceptionally effective at suppressing peripheral B-cell-mediated relapses, their list prices hover between $60,000…
-
Limitations of Oxygen Therapies
Underlying cardiovascular conditions can often exacerbate multiple sclerosis. Endothelial damage is a well-established autoimmune pathology; consequently, ischemic changes in both the brain and the myocardium, along with congenital heart rhythm abnormalities, frequently contribute to neurodegeneration. Crucially, this neurodegeneration can occur independently of autoimmune oligodendrocyte destruction and active demyelination. Patients with MS often report that oxygen…
-
Comparing MS Treatments – aHSCT vs NCT Explained
When you’re looking into treatments for Multiple Sclerosis, it helps to know that not all therapies aim to do the same thing. Two you might come across are NCT and aHSCT. Here’s a simple breakdown of what each one does, what it can’t do, the risks involved, and who’s actually a good candidate. In short The primary difference…